Is ChondroFiller injection available on the NHS?

ChondroFiller injection is not commissioned by NHS England and is not available at any NHS trust — that is the short answer, and it applies uniformly across the country.

This is not a postcode-lottery situation. There is no integrated care board (ICB), including those covering Lincolnshire, that currently funds the treatment. Patients sometimes assume that a specialist centre in London or a well-resourced trust elsewhere might offer it on the NHS; none do. The absence is a commissioning decision at national level, not a gap that varies by region or referral route.

NHS England periodically reviews newer orthobiologics, and it is possible that injectable scaffold treatments could enter future commissioning discussions. However, no active pathway exists today, and patients should not plan around a funding change that remains speculative.

For anyone weighing their options, the practical meaning is straightforward: ChondroFiller injection sits entirely within the self-funded private pathway. The remainder of this article sets out what private access looks like in terms of cost, what is available locally in Lincolnshire, and how the treatment compares with what the NHS does fund for hip cartilage.

What the NHS does offer for hip cartilage damage

The NHS does provide meaningful hip care at both ends of the clinical spectrum — but the options have clear boundaries.

For patients with early or moderate hip pain, standard NHS management begins with physiotherapy, lifestyle modification, and intra-articular injections: corticosteroid for acute inflammation or hyaluronic acid to support the joint environment. These first-line measures are widely available via GP referral or NHS musculoskeletal services and remain appropriate for many patients.

At the other end of the spectrum, total hip replacement is reliably funded across the NHS and, for patients with end-stage osteoarthritis and failed conservative care, represents the most robustly evidenced intervention available.

The gap sits between those two points. For patients with focal Grade III or IV hip cartilage defects who retain sufficient joint architecture to avoid replacement, the NHS has no funded regenerative pathway for the hip joint. Autologous Chondrocyte Implantation (ACI), which NHS England has funded since 2017, and Spherox, the approved cell-therapy product, are both commissioned for the knee only; the commissioning policy does not extend to the hip joint.

Two national specialist centres — the Cartilage Clinic at University Hospital Southampton and the Joint Cartilage Transplantation service at the Royal National Orthopaedic Hospital, which has completed over 1,500 procedures — do offer cartilage preservation services. Neither includes ChondroFiller injection.

For Lincolnshire patients with focal hip cartilage damage who are not yet candidates for replacement, this is the context that makes the private pathway the only currently available route to a regenerative treatment.

What ChondroFiller injection costs privately

Privately, ChondroFiller injection is priced across the UK at approximately £3,000 to £8,000 per treatment course — a range that reflects a single, well-defined variable: the number of boxes of collagen scaffold required.

The box count (one, two, or three) is determined by the area of cartilage damage. One box covers smaller focal defects; larger defects across more of the hip joint surface may need two or three. At the London Cartilage Clinic, the published prices are £3,000 for one box, £5,500 for two, and £8,000 for three, each inclusive of consultation, ultrasound guidance, the product, antibiotic cover, and a six-week follow-up appointment. The same pricing logic applies to hip applications.

The box count can only be confirmed after imaging review. Patients who receive a quote before a clinician has assessed their scans should treat that figure as provisional.

Lincolnshire Hip prices ChondroFiller injection at £2,995 per injection at its Grantham and Sleaford clinics — at the bottom of the national range and broadly comparable with London Cartilage Clinic's entry-level price, without the need to travel to London. Consultation fees and any imaging not already available should be factored into overall budgeting as separate items.

Because defect size is the primary cost driver, the right starting point for cost planning is a clinical assessment and up-to-date imaging rather than an assumption about which price tier applies.

Private medical insurance and ChondroFiller injection

Most patients holding private medical insurance (PMI) assume their policy will cover a procedure categorised as cartilage repair. For the ChondroFiller injection pathway, that assumption is incorrect: major UK insurers, including Bupa and AXA, do not routinely cover the outpatient injectable route.

The source of confusion is a real distinction. The arthroscopic version of the ChondroFiller procedure — delivered in a surgical setting under general or spinal anaesthesia — uses CCSD billing codes W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy), and pre-authorisation approvals have been achieved with Bupa, Aviva, and WPA for that route. That surgical route is not the pathway offered at Lincolnshire Hip, where ChondroFiller is delivered as an ultrasound-guided outpatient injection. Those surgical approvals do not transfer to the injection pathway.

Patients with an existing PMI policy should contact their insurer before booking a consultation — quoting the treatment name and the codes above — and obtain any approval in writing before proceeding. A call placed at the enquiry stage, rather than after a consultation fee has been paid, avoids a later cost surprise.

For the great majority of patients, the injectable ChondroFiller pathway is self-funded, and cost planning should begin from that baseline.

Getting ChondroFiller injection in Lincolnshire

For patients in Lincolnshire, the practical access question has a straightforward answer: the full ChondroFiller injection pathway is available locally, without travelling to London.

Lincolnshire Hip — led by Professor Paul Lee — offers ChondroFiller injection for focal hip cartilage damage at clinics in both Grantham and Sleaford. Consultation, imaging review, the injection itself, and post-treatment follow-up are all delivered at those local sites. Patients do not need to arrange a separate trip to a London facility for any stage of the pathway.

This matters in practical terms. Until recently, patients outside London researching ChondroFiller injection would most commonly encounter the London Cartilage Clinic on Harley Street — the first UK clinic to offer ChondroFiller as an injection, and still the main point of reference for patients willing to travel. For those based in Lincolnshire or the surrounding counties, an end-to-end local pathway removes a logistical barrier that has historically made specialist hip cartilage care feel out of reach.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a GP referral for hip assessment. A self-referral means that patients who have already been investigating their options — and have imaging or a working diagnosis — can book a consultation directly without waiting for a GP letter to open the pathway.

What to do before committing to the pathway

Before booking a consultation, a short preparation avoids cost surprises and sets realistic expectations.

Confirm the clinical target first. ChondroFiller injection is indicated for focal articular cartilage defects — typically Grade III or IV — in patients with preserved joint architecture. It is not suitable for diffuse hip osteoarthritis or end-stage joint disease. Patients unsure of their grade should review their imaging history before enquiring about the treatment specifically.

Arrange up-to-date MRI. No provider can confirm box count — and therefore final cost — without reviewing your hip imaging. A scan that is more than 12–18 months old is likely to be repeated before or at the first consultation. A clinic that quotes a price before seeing imaging is quoting without complete clinical information.

Check your PMI policy in writing. The injectable pathway is not routinely covered by Bupa or AXA. If you hold cover with Aviva or WPA, request written pre-authorisation — quoting CCSD codes W3111 and W8500 — before committing. Most patients will be self-funding, but written confirmation removes doubt.

Budget for the full pathway. The injection price does not cover consultation, imaging, or the six-week follow-up appointment; include all three in your cost planning.

Understand the evidence, not the headline. ChondroFiller injection promotes matrix-induced chondrogenesis — a biological recruitment of the patient's own progenitor cells into a collagen scaffold, not a structural replacement. Published data show 70–85% of patients achieving meaningful symptom relief at three to five years, with a mean Harris Hip Score improvement of +33 points in hip applications. That is a solid evidence base for an outpatient non-surgical procedure; individual outcomes vary.

The six-week follow-up is the first clinical checkpoint: it reviews symptom response and, where indicated, early MRI changes to assess whether scaffold integration is progressing as expected — giving both patient and consultant a clear read on how the treatment is working.